öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º¹ùæ¯
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º416

ËùÊôԺУ£º¹ãÖÝÖÐÒ½Ò©´óѧ
ËùÊôԺϵ£º301ÁÙ´²Ò©ÀíÑо¿Ëù
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼/²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º ѧ¿ÆÁìÓò
¿Æѧѧλ£ºÖÐÎ÷Ò½½áºÏÁÙ´²
Ñо¿ÁìÓò£º ѧ¿ÆÁìÓò
¿Æѧѧλ£ºÖÐÎ÷Ò½½áºÏÁÙ´² [ÊÕÆð]




¸öÈ˼òÊö :
¸öÈ˼òÊö
1961Äê11Ô³öÉú£¬½­Î÷¾Å½­ÈË£¬ºº×壬Öй²²úµ³Ô±£¬µ³Î¯¸±Êé¼Ç¡¢Ð£³¤£¬²©Ê¿£¬½ÌÊÚ£¬²©Ê¿Ñо¿Éúµ¼Ê¦¡£
Ö÷ÒªÈÙÓþ
1.¹ú¼Ò¿Æѧ¼¼Êõ½ø²½¶þµÈ½±£¬µ÷¸ÎÆôÊ໯×Ç·¨·ÀÖÎÌÇÖ¬´úлÎÉÂÒÐÔ¼²²¡»ù´¡ÓëÓ¦ÓÃÑо¿£¬¹úÎñÔº£¬ÅÅÃûµÚÒ»£¬2014Äê
2.Ê×½ìÈ«¹ú´´ÐÂÕùÏȽ±£¬ÈËÁ¦×ÊÔ´Éç»á±£Õϲ¿¡¢Öйú¿ÆЭ¡¢¿Æ¼¼²¿¡¢¹úÎñÔº¹ú×Ê£¬2017Äê
3.ºÎÁººÎÀû½±£¬ºÎÁººÎÀû»ù½ðί£¬2017Äê
4.ÖйúרÀûÓÅÐã½±£¬Ò»ÖÖÖÎÁƸß֬Ѫ֢µÄÒ©Î¹ú¼Ò֪ʶ²úȨ¾Ö£¬Î¨Ò»Íê³ÉÈË£¬2014Äê
5.ÖлªÖÐÒ½Ò©¿Æ¼¼½ø²½Ò»µÈ½±£¬ÒÔ¸ÎΪÊàµ÷Ö¬»¯×Ç·¨µÄʵÑéºÍÁÙ´²Ñо¿¼°Ó¦Óã¬ÖлªÖÐҽҩѧ»á£¬ÅÅÃûµÚÒ»£¬2012Äê
6.¹ã¶«Ê¡¿Æ¼¼½ø²½Ò»µÈ½±£¬·ÀÖÎÌÇÖ¬´úлÎÉÂÒÐÔ¼²²¡·½Ò©ÎïÖÊ»ù´¡¼°×÷ÓûúÀíÑо¿£¬¹ã¶«Ê¡ÈËÃñÕþ¸®£¬ÅÅÃûµÚÒ»£¬2012Äê
7.¹ã¶«Ê¡¿Æѧ¼¼Êõ½ø²½Ò»µÈ½±£¬ÖÐÒ©¸´·½·ÀÖθß֬Ѫ֢µÄÁÙ´²ÓëʵÑéÑо¿£¬¹ã¶«Ê¡ÈËÃñÕþ¸®£¬ÅÅÃûµÚÒ»£¬2008Äê
8.Ê׽조Îâ½×ƽҽҩ´´Ð½±¡±£¬Îâ½×ƽҽѧ»ù½ð»á£¬2012Äê
9.µÚÊ®½ì¡°¹ã¶«Ê¡¶¡Ó±¿Æ¼¼½±¡±£¬¹ã¶«Ê¡¿ÆЭ£¬2009Äê
10.¹ú¼ÒÎÀÉú¼ÆÉúÍ»³ö¹±Ï×ÖÐÇàÄêר¼Ò£¬¹ú¼ÒÎÀÉúºÍ¼Æ»®ÉúÓýίԱ»á£¬2015Äê
11.È«¹úÈý°ËºìÆìÊÖ£¬È«¹ú¸¾Áª£¬2012Äê
12.È«¹úÓÅÐã¿Æ¼¼¹¤×÷Õߣ¬Öйú¿ÆЭ£¬2012Äê
13.ÏíÊܹúÎñÔºÕþ¸®ÌØÊâ½òÌùר¼Ò£¬¹úÎñÔº£¬2011Äê
14.ÖлªÖÐҽҩѧ»á¡°Ò½Ò©¿Æ¼¼Ö®ÐÇ¡±£¬2011Äê
15.¹ã¶«Ê¡¡°°ÙÃûÄÏÔÁ½Ü³öÈ˲ÅÅàÑø¹¤³Ì¡±ÅàÑø¶ÔÏ󣬹㶫ʡί×éÖ¯²¿¡¢¹ã¶«Ê¡ÈËÁ¦×ÊÔ´ºÍÉç»á±£ÕÏÌü£¬2013Äê
16.¹ã¶«Ê¡ÃûÖÐÒ½£¬¹ã¶«Ê¡ÈËÃñÕþ¸®£¬2012Äê

¿ÆÑй¤×÷ :
¹¤×÷¾­Àú
1990ÄêÆðÔڹ㶫ҩ¿Æ´óѧÈνÌ£¬1997ÄêÖÁ2001Äê¼ä£¬ÎªÏã¸Û´óѧ¼æÖ°¸±½ÌÊÚ¡£2001ÄêÆäÈνÌÊÚ£¬Ö÷ÈÎҽʦ£¬2005Äê3ÔÂÈÎУ³¤ÖúÀí£¬2006Äê9ÔÂÈθ±Ð£³¤£¬2010Äê6ÔÂÈιãÖÝÖÐÒ½Ò©´óѧ¸±Ð£³¤£¬2013Äê4ÔÂÈι㶫ҩ¿Æ´óѧµ³Î¯¸±Êé¼Ç¼æ¼ÍίÊé¼Ç£¬2014Äê4ÔÂÆðÈι㶫ҩ¿Æ´óѧУ³¤¡£
ѧÊõ¼æÖ°
1.ÖйúÖÐÎ÷Ò½½áºÏѧ»á¸±»á³¤
2.Öйú¿ÆЭίԱ
3.ÊÀ½çÖÐҽҩѧ»áÁªºÏ»á´úл²¡öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á»á³¤
4.ÖйúÕûºÏҽѧԺÁªÃ˸±Ö÷ϯ
5.ÖйúÕûºÏҩѧÁªÃ˳£Îñ¸±Ö÷ϯ
6.ÔÁ¸Û°ÄÒ½Ò©²úҵЭͬ´´ÐÂÁªÃËÀíÊ»áÀíʳ¤
7.¹ã¶«Ê¡ÖÐÎ÷Ò½½áºÏѧ»á»á³¤
8.¹ã¶«Ê¡ÖÐҽҩѧ»á¸±»á³¤
9.¹ã¶«Ê¡½¡¿µ¹ÜÀíѧ»á¸±»á³¤
¿ÆÑÐÏîÄ¿
1.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÖصãÏîÄ¿£¬µ÷¸ÎÆôÊ໯×Ç·¨·ÀÖÎÌÇÄò²¡¹ÚÐIJ¡Ð§Ó¦Ìص㼰»úÖÆÑо¿£¨**£©£¬2016-2020
2.¹ú¼Ò¿Æ¼¼ÖØ´óרÏ¡°¸´·½ÕêÊõµ÷Ö¬·½¡±ÓÐЧ³É·ÖȺɸѡ¼°ÆäÐÂÒ©ÑÐÖÆ£¨2009zx09103-407£©£¬2009-2010
3.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¬µ÷¸Î½µÖ¬·½¶ÔCYP7A1ÐźÅͨ·µ÷¿Ø×÷ÓûúÖÆÑо¿£¨**£©£¬2012-2015
4.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¬´ÓFTZµ÷½Ú¸Îõ¥Ã¸µÄ»úÖÆÑо¿¡°µ÷¸Î½µÖ¬¡±ÐÂÀíÂÛ£¨**£©£¬2010-2012
5.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¬¡°¸´·½ÕêÊõµ÷Ö¬·½¡±½µÑªÖ¬×÷ÓûúÀí¼°Ò©Ð§ÎïÖÊ»ù´¡Ñо¿(**)£¬2009
6.¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðÍŶÓÏîÄ¿£¬»ùÓÚµ÷¸Î½µÖ¬ÐÂѧ˵µÄ¸ß֬Ѫ֢ÖÐÒ½Ö¤ºò¼°Æä·ÀÖη½Ò©Ñо¿£¬£¨**000000£©£¬2010-2014
7.¹ã¶«Ê¡¿Æ¼¼Ìü¹ú¼ÊºÏ×÷ÏîÄ¿£¬»ùÓÚÌÇ×éѧ¼¼ÊõµÄ×é·ÖÖÐÒ©µ÷½ÚÌÇÖ¬´úлµÄ»úÖÆÑо¿£¨2015A**£©£¬2015-2016
8.¹ã¶«Ê¡½ÌÓýÌü²úѧÑнáºÏÏîÄ¿£¬ÖÐÒ©×é·ÖÐÂÒ©Ìï»Æ½µÖ¬Æ¬µÄÑз¢£¨2011B**£©£¬2012-2014
9.¹ã¶«Ê¡½ÌÓýÌü´´ÐÂǿУÏîÄ¿£¨¹ú¼Ò¼¶ÖØ´óÅàÓý³É¹û£©£¬ÖÐÎ÷Ò½½áºÏ·ÀÖÎÖ¬·¾¸Î»ù´¡Ñо¿ÓëÓ¦Óã¬2012-2014
10.¹ã¶«Ê¡½ÌÓýÌü´´ÐÂǿУÏîÄ¿£¨¹ú¼Ò¼¶ÖØ´óÅàÓýÏîÄ¿£©£¬»ùÓÚÖ¬·¾·Ö»¯Ì½ÌÖÒȵºËصֿ¹²¡ÀíÉúÀí»úÖÆÑо¿£¬2012-2014


Ö÷ÒªÂÛÎÄ
1.RegionalizationofHabitatSuitabilityofMasson'sPinebasedongeographicinformationsystemandFuzzyMatter-ElementModel.SciRep,2016Oct36:34716.doi:10.1038/srep34716£¨Í¨Ñ¶×÷Õߣ©
2.A-FABPmediatesadaptivethermogenesisbypromotingintracellularactivationofthyroidhormonesinbrownadipocytes.NatCommun.2017Jan278:14147.doi:10.1038/ncomms14147.£¨¹²Í¬×÷Õߣ©
3.HypocholesterolemiaofCoptidisalkaloidsisrelatedtothebileacidbyupregulatingCYP7A1inhyperlipidemicrats.Phytomedicine,2012,19(8-9):686-92£¨Í¨Ñ¶×÷Õߣ©
4.AnewTCMformulaFTZlowersserumcholesterolbyregulatingHMG-CoAreductaseandCYP7A1inhyperlipidemicrats,JournalofEthnopharmacology,2011,(135):299-307.£¨µÚÒ»×÷Õߣ©
5.LipidRegulatingEffectofTraditionalChineseMedicine£ºMechanismsofActions.Evidence-BasedComplementaryandAlternativeMedicine,2012,doi:10.1155/2012/970635(ͨѶ×÷Õß)
6.Invitroscreeningforanti-hepaticsteatosisactivecomponentswithinCoptidisRhizomaalkaloidsextractusinglivercellextractionwithHPLCanalysisandafreefattyacid-inducedhepaticsteatosisHepG2cellassay.Evidence-BasedComplementaryandAlternativeMedicine,2013,doi:10.1155/2013/459390.(ͨѶ×÷Õß)
7.TheChineseherbalmedicineFTZattenuatesinsulinresistanceviaIRS1andPI3Kinvitroandinratswithmetabolicsyndrome.JournalofTranslationalMedicine,2014,12:47(ͨѶ×÷Õß)
8.PotentialsynergisticeffectsofChineseherbalprescriptionFTZcomponentsdetectedinbloodtowardshepaticlipid-modulatingtargets.ComplementTherMed.201422(5):887-93.(ͨѶ×÷Õß)
9.StimulatingeffectofanewtriterpenederivedfromAnoectochiluselwesiionglucoseuptakeininsulin-resistanthumanHepG2cells.NatProdRes.2014,1-6.(ͨѶ×÷Õß)
10.RapididentificationofcoumarinsfromFructuscitriSarcodactylisbyUPLC/Q-TOF-MS.NatProdRes.201529(1):53-8.(ͨѶ×÷Õß)
11.AnalysisoftheConstituentsinRatSerumafterOralAdministrationofFufangZhenzhuTiaozhiCapsulebyUPLC-Q-TOF-MS/MS£ºChromatographia,2012,75(3-4):111-129(ͨѶ×÷Õß)
12.EffectsofFufangZhenzhuTiaozhiPrescription,AChineseherbalpreparation,onatherosclerosisinApoE-/-miceandrelatedmechanisms.ChinJIntegrMed.2011.(ͨѶ×÷Õß)
13.Liver-Adiposetissuecrosstalk:akeyplayerinthepathogenesisofglycolipidmetabolicdisease.ChinJIntegrMed.2017(ͨѶ×÷Õß)
14.ResearchProgressonPreventionandTreatmentofGlucolipidMetabolicDiseasewithIntegratedTraditionalChineseandWesternMedicine*.ChinJIntegrMed.2017(ͨѶ×÷Õß)
15.¸ß֬Ѫ֢סԺ»¼ÕßÖÐÒ½Ö¤ºòÁÙ´²Ñо¿.ÖйúÖÐÎ÷Ò½½áºÏÔÓÖ¾£¬2012£¬3£¨10£©£º1322-1325£¨Í¨Ñ¶×÷Õߣ©
16.¸´·½ÕêÊõµ÷Ö¬½ºÄÒ¶Ô¶¯ÂöÖàÑùÓ²»¯ÍÃÖ¬ÖʹýÑõ»¯¼°ÄÚƤ¹¦ÄܵÄÓ°Ïì,ÖйúÖÐÎ÷Ò½½áºÏÔÓÖ¾.2011,31(6):816-819£¨Í¨Ñ¶×÷Õߣ©
17.¸´·½ÕêÊõµ÷Ö¬½ºÄÒ¶Ô´óÊó·Ç¾Æ¾«ÐÔÖ¬·¾¸Îµ÷Ö¬±£¸Î×÷Óü°»úÖÆÑо¿£¬ÖвÝÒ©£¬2011£¬10£¨42£©£º2047-2077£¨Í¨Ñ¶×÷Õߣ©ÔÙÂÛ¸ÎÔÚ¸ß֬Ѫ֢·¢²¡ÖеĵØλºÍ×÷ÓÃ.ÐÂÖÐÒ½,2011,43£¨2£©:1-3.£¨Í¨Ñ¶×÷Õߣ©
18.ÌÇÖ¬´úл²¡Ó뾫׼ҽѧ.ÊÀ½ç¿Æѧ¼¼Êõ-ÖÐÒ½Ò©ÏÖ´ú»¯£¬2017£¬19£¨1£©£º50-54

½ÌÓý±³¾° :
1984Äê±ÏÒµÓÚ½­Î÷ÖÐҽѧԺÖÐҽѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬»ñѧʿѧλ¡£
1987ÄêÖÁ1990Äê±ÏÒµÓÚ¹ãÖÝÖÐÒ½Ò©´óѧÖÐÒ½Õï¶ÏѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬»ñ˶ʿѧλ¡£
2006Äê±ÏÒµÓÚµÚÒ»¾üÒ½´óѧ£¨ÏÖÄÏ·½Ò½¿Æ´óѧ£©ÖÐÎ÷Ò½½áºÏÁÙ´²öλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬»ñ²©Ê¿Ñ§Î»¡£